Evidence map›Paper›PMID 29997463›Full record

ArticleCurrent urology2018

Prostate Cancer Detection with Multiparametric MRI: A Comparison of 1 M-Concentration Gadobutrol with 0.5 M-Concentration Gadolinium-Based Contrast Agents.

Takeshi Hara, Takeshi Ogata, Hiroko Wada, Takayuki Yabuki, Susumu Kanazawa

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Current urology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 6 citations in OpenAlex.

  1. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Takeshi HaraDepartment of Radiology, NHO Iwakuni Clinical Center, Yamaguchi.
Takeshi OgataDepartment of Radiology, NHO Iwakuni Clinical Center, Yamaguchi.
Hiroko WadaDepartment of Radiology, NHO Iwakuni Clinical Center, Yamaguchi.
Takayuki YabukiDepartment of Radiology, NHO Iwakuni Clinical Center, Yamaguchi.
Susumu KanazawaDepartment of Radiology, Okayama University, Okayama, Japan.
Iwakuni Medical Center · JPOkayama University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionGadobutrol (Gd-DO3A-butrol) (Gadovist®) is a macrocyclic gadolinium-based contrast agent for magnetic resonance imaging (MRI) formulated at 1.0 mmol Gd/ml. Gadobutrol's higher concentration compared to other contrast agents (0.5 mmol Gd/ml) is associated with higher T1 relaxivity. We examined whether gadobutrol increases the accuracy of prostate cancer detection using dynamic contrast-enhanced MRI. MATERIALS AND

methodsMultiparametric MRI was performed in 379 patients: 94 patients received 1 M gadobutrol while 285 randomly received equivalent doses of 0.5 M gadoterate meglumine or gadopentetate dimeglumine. MRI images were retrospectively and blindly assessed for the presence of cancer by comparing them with prostate biopsy findings.

resultsThe specificity and accuracy were significantly higher with 1 M gadobutrol than 0.5 M of the other contrast agents. There were no significant differences in the sensitivity, or positive and negative predictive values.

conclusionMultiparametric MRI using 1 M gadobutrol may improve the accuracy of prostate cancer detection.

Indexed as

Contrast mediaGadoliniumMagnetic resonance imagingProstatic neoplasms

Identifiers

PMID29997463
PMCPMC6036578
OpenAlexW2805927262

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.